Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide ...

Three years ago, Spycher’s peptide linker work spun out from PSI and ETH Zurich. The main reason for that move was Spycher’s great desire to incorporate a company.

Researchers at Araris Biotech AG have developed antibody-drug conjugate (ADC) technology that allows single-step connection of antibody to drug via a novel RKAA peptide linker that stably prevents the ...

The platform consists of a pH-Low Insertion Peptides (pHLIPs®) peptide, linker, and small molecule anti-cancer agent. pHLIP peptides are a family of pH-Low Insertion Peptides that target acidic ...

Recently, the glucago*-like peptide-1 receptor (GLP-1R) has become a primary target in diabetes and obesity treatment because of its role in controlling blood sugar and weight. Peptide-based GLP ...

This dodecahedral link structure, measuring 6.3 nanometers in diameter, was achieved by combining geometric principles derived from knot theory and graph theory with peptide engineering.

Araris’s small-peptide linkers can form strong, site-specific bonds to off-the-shelf antibodies, creating stable and potent ADCs. Taiho expects to complete the acquisition in the first half of 2025.

Micurx Pharmaceuticals Inc. has patented peptide-drug conjugates consisting of peptide targeting kidney cells covalently linked to an anti-inflammatory or immunomodulating or nephron-protective drug ...

“The antimicrobial peptide psoriasin, encoded by S100A7 is a member of the S100 protein family and has been detected in the urinary tract,” the team further explained.